TY - JOUR
T1 - Prognostic role of braf mutations in colorectal cancer liver metastases
AU - Pikoulis, Emmanouil
AU - Margonis, Georgios A.
AU - Andreatos, Nikolaos
AU - Sasaki, Kazunari
AU - Angelou, Anastasios
AU - Polychronidis, Georgios
AU - Pikouli, Anastasia
AU - Riza, Elena
AU - Pawlik, Timothy M.
AU - Antoniou, Efstathios
PY - 2016/9
Y1 - 2016/9
N2 - Background/Aims: The impact of tumor biology on prognosis in patients with colorectal liver metastasis (CRLM) has been the topic of intense research. Specifically, the presence of BRAF mutations has been recently associated with adverse long-term outcomes. We examined the existing literature on the prognostic implications of BRAF mutations in patients with CRLM. Materials and Methods: A structured review of the literature was performed between 5/1/2016 and 6/1/2016 using the PubMed database. Original research articles published between 1/1/2010 and 4/01/2016 were considered eligible. The primary end-points were overall survival (OS)/disease-specific survival (DSS) and recurrence-free survival (RFS) among patients with BRAF mutated CRLM who underwent resection. Results: Eight studies were included. All studies reported on OS/DSS, while 6 reported on RFS. BRAF mutant status was a strong independent predictor of both worse OS/DSS and RFS in 7 and 4 studies, respectively. Conclusion: BRAF-mutant lesions are consistently associated with poor prognosis. Consequently, the indications of CRLM resection in this patient group should be reconsidered.
AB - Background/Aims: The impact of tumor biology on prognosis in patients with colorectal liver metastasis (CRLM) has been the topic of intense research. Specifically, the presence of BRAF mutations has been recently associated with adverse long-term outcomes. We examined the existing literature on the prognostic implications of BRAF mutations in patients with CRLM. Materials and Methods: A structured review of the literature was performed between 5/1/2016 and 6/1/2016 using the PubMed database. Original research articles published between 1/1/2010 and 4/01/2016 were considered eligible. The primary end-points were overall survival (OS)/disease-specific survival (DSS) and recurrence-free survival (RFS) among patients with BRAF mutated CRLM who underwent resection. Results: Eight studies were included. All studies reported on OS/DSS, while 6 reported on RFS. BRAF mutant status was a strong independent predictor of both worse OS/DSS and RFS in 7 and 4 studies, respectively. Conclusion: BRAF-mutant lesions are consistently associated with poor prognosis. Consequently, the indications of CRLM resection in this patient group should be reconsidered.
KW - BRAF
KW - CRLM
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=84991573148&partnerID=8YFLogxK
U2 - 10.21873/anticanres.11040
DO - 10.21873/anticanres.11040
M3 - Article
C2 - 27630332
AN - SCOPUS:84991573148
SN - 0250-7005
VL - 36
SP - 4805
EP - 4811
JO - Anticancer research
JF - Anticancer research
IS - 9
ER -